预约演示
SERB Pharmaceuticals acquires US rights for bentracimab from SFJ
2023-05-12
上市批准临床3期突破性疗法优先审批并购
Bentracimab is designed to reverse the antiplatelet activity of ticagrelor. Credit: aodaodaodaod on Shutterstock.com.
Bentracimabpharmaceutical company SERB Pharmaceuticals has acquiticagrelorive US rights for bentracimab from SFJ Pharmaceuticals.
SFJ Pharmaceuticals will lead the SERB Pharmaceuticalsal of bentracimab.bentracimabSFJ Pharmaceuticals
ReportsCOVID-19: Contract Pharmaceutical Development and Manufacturing Relationships GlobalData
ReportsGlobal Mergers and Acquisitions (M&A) Deals in Pharma 2021 - Thematic Research GlobalData
View all
In partnership with SERB Pharmaceuticals, the company will also file a biologics licence application (BLA) to the US Food and Drug Administration (FDA) later this year.
The new monoclonal antibody fragment bentracimab is dePharma to reverse the antiplatelet activity of ticagrelor, a reversible oral P2Y12 platelet inhibitor.
Marketed as Brilinta by AstraZeneca, ticagrelor has been developed for heart attack or stroke patients and those with acute coronary syndromes and coronary artery disease (CAD).
Subject to receivingSERB Pharmaceuticalsacimab will allow these patients to benefit from the antithrombotic effect ofFood and Drug Administration (FDA) death risk and preventing vascular events.
SERB Pharmaceuticals executive chairmbentracimabUrbain stated: “The acquisition of bentracimab marks ticagrelorant step in our straP2Y12 platelet inhibitorestment in innovative biologic products for critical care conditions and leverages our existing commercial and technical capabilities.
“We’re excitBrilintartneAstraZeneca rticagrelorleaders in late-stage drheart attacknt, strokeng this life-saving medicacute coronary syndromessionacoronary artery disease (CAD)t.”
Interim analysis fromFDAe ongoing PbentracimabVERSE-IT trial showed that bentracimab quickly and sustainably reversed ticagrelor’s antiplatelet effects.
SERB Pharmaceuticalsell-tolerated, with only minor adverse events observed.bentracimab
The US FDA granted breakthroughSFJerapy designation to bentracimab in 2019.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。